Downloaded 166 times
Uploaded bySonali Subhadarshini
Dr. Reddy's Lab - Business Model
Dr. Reddy's Laboratories, founded in 1984 in Hyderabad, aims to be India's first global pharmaceutical company, focusing on innovative medicines to improve health. The company specializes in active pharmaceutical ingredients, generics, and biologics, with operations in around 100 countries and significant revenue growth since its establishment. Despite achieving notable milestones, including a NYSE listing and various acquisitions, Dr. Reddy's faces challenges like patent litigations and quality issues impacting its financial performance.
MarketingâŚ
More Related Content
Similar to Dr. Reddy's Lab - Business Model
![[rokonz.com] Glossary of Semantic SEO Part-2.pdf](https://cdn.slidesharecdn.com/ss_thumbnails/rokonz-260123200719-92199ba8-thumbnail.jpg?width=640&height=640&fit=bounds)
Dr. Reddy's Lab - Business Model
- 1.
- 2. Mission & Vision Mission: To be India's first pharmaceutical that successfully takes its products from discovery to commercial launch globally. Vision : To become a discovery ruled global pharmaceutical company with a core purpose of helping people lead healthier lives.
- 3. ⢠Founded- 1984 â˘Key people- Anji Reddy (Founder) G. V. Prasad (CEO) Kallam Satish Reddy(Chairman) ⢠Headquarter- Hyderabad, Telangana, India ⢠Revenue- $2.3 billion (2014) ⢠Net income- $350 million (2014) ⢠Number of employees- 20000 (April 2015) Company Profile
- 4. Background ďź Produces andsells active pharmaceutical ingredients , finished dosages and biologics. ďź Manufactures ulcer medicines, antibiotics, pain relievers, antidepressants and cardiovascular drugs. ďź Markets its product in approximately 100 countries , focusing on Europe, India, US and Russia. ďź On 11 April 2001, Dr. Reddyâs became the first pharmaceutical company from Asia Pacific to be listed on New York stock exchange. ďź Research and development in diabetes, cancer, cardiovascular diseases and bacterial infections.
- 5. ďź 135 newgeneric products, filing of 107 new product registration, and 56 drug master files ďź Integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. ďź Offers a portfolio of products and services including ⢠Active Pharmaceutical Ingredients (APIs) ⢠Custom Pharmaceutical Services (CPS) ⢠Generics ⢠Biosimilar ⢠Differentiated formulations ⢠New Chemical Entities (NCEs). Background contd.
- 6.
- 7. Expansions & Acquisitions ďźOut-licensed a molecule for clinical trials to Novo Nordisk, a Danish pharmaceutical company in 1997 ďź Acquisition of Benzex laboratories in 1988 ďź Dr. Reddyâs research foundation (DRF) was established in 1993 ďź Strengthened its Indian manufacturing operations by acquiring American Remedies Ltd. in 1999 ďź Became the third largest pharmaceutical company in India ďź In December 2000, Reddyâs had undertook its first commercial launch of a generic product in the USA. ďź Became the first non-Japanese pharmaceutical company from the Asia-Pacific region to obtain a New York Stock Exchange listing
- 8. ďź Merger withCheminor Drugs in 2000 was a big leap, rose as the third largest pharmaceutical company. ďź Acquisition of Betapharm in 2006 (US$ 570 millions) ďź (2007) Revenues reached US$1.5 billion and recognition as no 1 pharmaceutical company in India in terms of turnover, rise to $1.7 billions by 2011 ďź Joint venture with Fujifilm Expansions & Acquisitions contd.
- 9. DRL: The rise.. ďźQuick rise in the pharmaceutical sector in the late 80s and early 90s. ďź Launch of new products ensured continued growth ďź Focus on R&D acted as a booster in growth and reputation ďź Acquisition of domestic and foreign companies were a major milestone ďź Joint ventures, patents and licensing were contributing factors
- 10. ďź Patient litigationsin the US market ďź Quality problems in Mexico unit ďź Falling revenues in key markets ďź String of fatal accidents DRL: The fall..
- 11. ďźAustralia ďźChina ďźGermany ďźNew Zealand ďźRomania ďźRussia &CIS ďźSouth Africa ďźUnited Kingdom ďźUnited States of America Presence besides India
- 12. There is nodiet that will do what eating healthy doesâŚ
- 13.
- 14. ⢠National SecuritiesDepository Ltd. ⢠Central Depository Services (I) Ltd. ⢠J P Morgan Chase Bank ⢠Bombay Stock Exchange ⢠National Stock Exchange ⢠New York Stock Exchange Inc Supplierâs of capitalâŚ
- 15. Some of theinvestors⌠⢠Kedar Upadhye 7-1-27, Ameerpet, Hyderabad - 500016. Telangana (India). Ph: +91 40 6683 4297 Email: kedaru@drreddys.com ⢠Ashish Girotra Ph: +1 609 375 9805 Email: ashishg@drreddys.com ⢠Saunak Savla Ph: +91-40-4900 2135 Email: saunaks@drreddys.com
- 16.
- 17. Therapeutic areas ⢠Gastro-Intestinal â˘Cardiovascular ⢠Pain Management ⢠Anti-Infective ⢠Dermatology ⢠Diabetology ⢠Nutraceuticals ⢠Oncology ⢠Respiratory ⢠Stomatologicals ⢠Urology ⢠Gynaecology ⢠Haematology ⢠Paediatric ⢠Central Nervous System
- 18.
- 19.
- 20. Products Branded Generics API Cardiovascular Valsartan Telmisartan Ranolazine Ramipril Celecoxib Ketorolac Tromethamine Naproxen Ritonavir Lopinavir Fluconazole AbacavirBase Atocor Betaone Cardiopril Stamlo Finrid Hilin Ketoro Nise Relent Oxit Clamp Ciprolet Pain Management Anti infective
- 21. NCE Differentiated products Biosimilar Grafeel Reditux Cresp Peggrafeel Bacterial Infections Metabolic Disorders Pain and Inflammation Promiseb⢠Topical Cream Scytera Foam ClodermŽ Cream Products contd.
- 22. Distributor Euphoria Healthcare PvtLtd P D Doshi & Company Kaivan Distributors Dr Reddys Laboratories Ltd Biodiesel Technologies Mehta Medicare Pvt Ltd Bio Square Life Sciences Srs Enterprises Surya pharmaceuticals Mumbai Kolkata Chennai
- 23. ROW, 6, 6% NORTHAMERICA, 45, 45% EUROPE, 12, 12% INDIA, 18, 18% RUSSIA & CIS, 19, 19% REVENUE DISTRIBUTION GEOGRAPHICAL MIX ROW NORTH AMERICA EUROPE INDIA RUSSIA & CIS CustomersâŚ
- 24. Financial aspects 0 500 1000 1500 2000 2500 FY08 FY09FY10 FY11 FY12 FY13 FY14 1241 1509 1481 1639 2019 2149 2300 REVENUEIN$MILLION FISCAL YEAR
- 25.
- 27. Applied R &D Basic R & D Local Branding Global Branding CIPLA Torrent NOVO NORDISK Glaxo Smithkline SANOFI-AVENTIS DR. REDDYâS LAB RANBAXY International Formulation Domestic Formulation Torrent Cipla Generics Strategic groups in the Indian pharma industry
- 28. Partnerships with keyplayers in the market keeps its cost base down Research Driven & Global Take a drug all the way to market Take a molecule from its pipeline all the way to the market place cost-effectively market Increase domestic footprint in generics Over-reliance on partnerships Lack of resources similar to US and Europe based competitors to develop a drug to marketing Needs to gain FDA approval for all sources and products Products have to pass strict FDA trials before going to market, which can be costly and time consuming Strength Weakness ThreatOpportunity SWOT Analysis